Incyte Corporation ($INCY) Stock Forecast: Up 5.1% Today

What is Incyte Corporation?

Asset Incyte Corporation (NASDAQ: INCY) operates in the biopharmaceutical sector, specializing in the development and distribution of proprietary therapeutics to combat various diseases. The company has gained recognition for its groundbreaking treatments across multiple medical fields.

Why is Incyte Corporation going up?

INCY stock is up 5.1% on Mar 17, 2025 17:15

• Today's surge in Incyte's stock value is a direct result of the successful outcomes from the Phase 3 STOP-HS trials for their latest chronic skin disease medication, Povorcitinib.
• Initial hesitance in the stock price during pre-market trading, attributed to mixed reviews of the trial data, was overshadowed by the drug's effectiveness in patients previously treated with biologics, along with the positive rates of HiSCR50.
• Furthermore, the positive reception towards Incyte's pioneering treatments is reinforced by the promising results of an FDA-approved drug, a collaboration with Eli Lilly, which showed substantial efficacy in young patients grappling with patchy hair loss.
• The continuous progress in Incyte's product pipeline and its commitment to addressing unmet medical needs have instilled confidence in investors regarding the company's potential for future growth, fueling the optimistic upturn in the stock value.

INCY Price Chart

INCY Technical Analysis

INCY News

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls - Incyte ( NASDAQ:INCY )

Incyte's Phase 3 STOP-HS trials showed povorcitinib met primary endpoints, with up to 42.3% of patients achieving HiSCR50 at Week 12. Povorcitinib demonstrated greater efficacy in biologic-experienced HS patients, with HiSCR50 rates reaching 45% in the STOP-HS2 trial.

https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Incyte ( NASDAQ:INCY ) , Affirm Holdings ( NASDAQ:AFRM )

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Incyte Corporation INCY fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis ...

https://www.benzinga.com/25/03/44355350/incyte-tesla-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

Incyte ( INCY ) Up 2.6% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

https://www.zacks.com/stock/news/2429150/incyte-incy-up-26-since-last-earnings-report-can-it-continue

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss - Eli Lilly ( NYSE:LLY ) , Incyte ( NASDAQ:INCY )

At Week 36, 60% on baricitinib 4 mg and 36.9% on 2 mg saw at least 50% improvement, compared to 5.7% on placebo. 50% on baricitinib 4 mg and 24.1% on 2 mg had significant eyebrow regrowth, while none on placebo saw similar results. Find out which stock just claimed the top spot in the new ...

https://www.benzinga.com/general/biotech/25/03/44245346/eli-lilly-incyte-partnered-fda-approved-drug-shows-encouraging-efficacy-in-adolescent-patients-wi

Trending Today

TRON ($TRX) Crypto Forecast: Up 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 6.0% Today

Ondo ($ONDO) Crypto Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 5.2% Today

Bonk ($BONK) Crypto Forecast: Up 14.0% Today

Sei ($SEI) Crypto Forecast: Up 6.7% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

Movement ($MOVE) Crypto Forecast: Up 5.8% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.0% Today

Curve DAO Token ($CRV) Crypto Forecast: Up 14.0% Today

Incyte Corporation Price History

05.08.2024 - INCY Stock was down 5.8%

• The bearish movement in INCY today could be attributed to profit-taking following a recent uptrend or market uncertainties regarding the company's future performance.
• Recent discussions on INCY's earnings report likely impacted investor sentiment, potentially contributing to the bearish movement.
• Concerns about INCY's ability to meet earnings estimates may be fueling the downward pressure on the stock price.

29.09.2024 - INCY Stock was up 9.1%

• INCY showed strong bullish momentum today, believed to be driven by the upcoming positive third-quarter earnings expectations.
• The anticipated rise in sales of Jakafi and Opzelura could have contributed to investor confidence in the company's financial outlook.
• There is a sense of positivity among investors regarding INCY's revenue growth potential, leading to an increase in the stock price during today's trading.

29.09.2024 - INCY Stock was up 10.2%

• Despite missing earnings estimates, INCY experienced a bullish movement due to beating revenue expectations on the back of increased sales of Jakafi and Opzelura.
• The market seems to be focusing more on the positive revenue beat and the potential growth prospects indicated by higher product sales.
• Investors may be optimistic about the company's future performance, overlooking the slight earnings miss as they anticipate continued success driven by strong sales of key products.

06.10.2024 - INCY Stock was up 6.0%

• Strong third-quarter revenue was reported by Incyte (INCY), driven by a significant increase in Jakafi net product revenues, fueled by a 10% rise in total demand.
• The stock was upgraded by analysts post the positive revenue results, showing increasing confidence in the company's performance.
• Comparisons of value with BioMarin Pharmaceutical (BMRN) suggest that Incyte (INCY) may be considered an undervalued stock, potentially attracting more investors and contributing to the bullish movement.

09.11.2024 - INCY Stock was down 5.1%

• Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The overall market for biopharmaceutical companies can be volatile, with stock movements often influenced by clinical trial results and drug approvals.
• ASSESSMENT:
• Despite Incyte's positive news of meeting primary and secondary goals in a late-stage study for lung cancer treatment, the stock experienced a bearish movement.
• A comparison between Exelixis (EXEL) and Incyte (INCY) might have led investors to reassess the value of INCY, potentially contributing to the bearish trend.
• Investors may have been expecting even more positive results from the study, leading to profit-taking and a temporary dip in the stock price.
• Market sentiment or broader industry trends could have influenced the bearish movement, despite the positive clinical trial outcomes for Incyte.

19.10.2024 - INCY Stock was down 9.2%

• Incyte Corporation (INCY) stopped enrolling participants in a phase II study of MRGPRX2 in Chronic Spontaneous Urticaria (CSU) due to preclinical toxicology findings, leading to investor apprehension.
• The suspension of enrollment in the study of MRGPRX2 in CSU created a pessimistic atmosphere around Incyte Corporation, contributing to the downward trend in the stock.
• Shareholders responded by selling INCY shares, causing a drop in the stock price as uncertainties about the study's future impact on the company's pipeline surfaced.

19.10.2024 - INCY Stock was down 12.3%

• INCY stock experienced a strong bearish movement following the announcement of a pause in enrollment for a Phase 2 study due to preclinical toxicology findings.
• The decision to halt the study in chronic spontaneous urticaria (CSU) likely raised concerns among investors about the potential impact on future drug development and revenue.
• The negative news surrounding INCY's clinical trial setback contributed to the bearish trend in the stock price as investors reacted to the uncertainty surrounding the company's pipeline and prospects in the biopharmaceutical sector.

11.02.2025 - INCY Stock was down 2.7%

• Positive phase III study results for Opzelura in treating prurigo nodularis may have heightened investor expectations.
• The significant downward movement in INCY's stock suggests the market may have factored in the positive outcomes already, resulting in a sell-off post-announcement.
• Investors seem to be capitalizing on the news by selling for profit, causing a temporary decline in the stock price despite Opzelura's promising efficacy results.

11.02.2025 - INCY Stock was down 5.7%

• INCY is the stock symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.
• ASSESSMENT:
• The bearish movement in INCY stock today could be due to profit-taking by investors after a strong positive run following the news of Opzelura's superior efficacy in prurigo nodularis studies.
• Despite the positive data from the phase III studies and the encouraging efficacy of their partnered FDA-approved drug, investors may have been expecting even better results, leading to a sell-off.
• The market might be reacting to concerns about the sustainability of the positive outcomes reported, leading to a temporary dip in the stock price.

10.01.2025 - INCY Stock was down 5.0%

• INCY stock had a bearish day attributed to the company's Q4 earnings that fell short of estimates by -6.54%.
• A revenue surprise of 2.63% may have contributed to the negative market sentiment towards the stock.
• Concerns among investors about the company's performance in key metrics for the quarter ended December 2024 are evident.
• The market's response suggests uncertainties about INCY's future, potentially driving the bearish trend.

10.01.2025 - INCY Stock was down 4.6%

• There was unusual options activity indicating a bullish sentiment among deep-pocketed investors, but it did not result in a positive market movement for Incyte today.
• Incyte reported mixed Q4 earnings with revenue surpassing estimates but earnings falling short, which seemed to drive the bearish movement.
• Despite strong sales of key products in Q4 and a positive outlook for 2025 with upcoming launches, the disappointment from the earnings miss contributed to the stock price decline.
• Investors may be exercising caution regarding the future trajectory of Incyte's stock due to the unexpected earnings results and the need for further clarity on the company's financial performance in the coming quarters.

17.02.2025 - INCY Stock was up 5.1%

• Today's surge in Incyte's stock value is a direct result of the successful outcomes from the Phase 3 STOP-HS trials for their latest chronic skin disease medication, Povorcitinib.
• Initial hesitance in the stock price during pre-market trading, attributed to mixed reviews of the trial data, was overshadowed by the drug's effectiveness in patients previously treated with biologics, along with the positive rates of HiSCR50.
• Furthermore, the positive reception towards Incyte's pioneering treatments is reinforced by the promising results of an FDA-approved drug, a collaboration with Eli Lilly, which showed substantial efficacy in young patients grappling with patchy hair loss.
• The continuous progress in Incyte's product pipeline and its commitment to addressing unmet medical needs have instilled confidence in investors regarding the company's potential for future growth, fueling the optimistic upturn in the stock value.